Genespire
The promise of a cure
Milan, Italy · Founded 2020 · $69.4M raised
- Headquarters
- Milan
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- genespire.com
- Total Funding
- $69.4M
- Last Round
- $52.0M Series BSep 2024
- Rounds
- 2
About
Genespire is a preclinical-stage biotechnology company based in Milan, Italy, focused on developing next-generation gene therapies using immune-shielded lentiviral vectors for children with severe genetic diseases. Founded as a spin-off from SR-Tiget (San Raffaele Telethon Institute for Gene Therapy) in March 2020, the company's lead program GENE202 targets methylmalonic acidaemia (MMA) and has received Orphan Drug Designation from both the FDA and the European Commission. Genespire's approach combines proprietary vector engineering with deep clinical expertise from its academic founders to create potentially curative, single-dose treatments for lysosomal storage and other rare inherited disorders.
Summary
Genespire is a Biotech company based in Milan, Italy, founded in 2020. It has raised $69.4M in total across 2 rounds, most recently a $52.0M Series B round in Sep 2024. Investors include Sofinnova Partners, XGEN Venture and CDP Venture Capital SGR.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...